Management of ST-Elevation Myocardial Infarction (STEMI)

Initial Diagnosis and Assessment

• The European Society of Cardiology recommends that twelve-lead ECG recording and interpretation should be obtained as soon as possible at first medical contact, with a maximum target delay of 10 minutes 1
• ECG monitoring with defibrillator capacity should be initiated immediately in all patients with suspected STEMI, as recommended by the European Society of Cardiology 1
• Routine oxygen therapy is not recommended in patients with oxygen saturation ≥90%, according to the European Society of Cardiology 1

Reperfusion Strategy

• The European Society of Cardiology recommends that primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy when performed by an experienced team within 120 minutes of STEMI diagnosis 2, 3
• Patients should be transferred directly to the catheterization laboratory, bypassing the emergency department, as recommended by the European Society of Cardiology 2, 4
• PCI-capable centers should deliver 24/7 service and perform primary PCI without delay, according to the European Society of Cardiology 4
• Aspirin (oral 150-325 mg or IV 250-500 mg if unable to swallow) should be administered as soon as possible, as recommended by the European Society of Cardiology 5, 2
• A potent P2Y12 inhibitor (prasugrel or ticagrelor, or clopidogrel if these are unavailable) should be administered before or at the time of PCI, according to the European Society of Cardiology 2, 6
• Anticoagulation during PCI should be provided with unfractionated heparin (UFH) as an IV bolus at 100 U/kg (60 U/kg if GPIIb/IIIa inhibitors are used), as recommended by the European Society of Cardiology 5
• Fondaparinux is not recommended for primary PCI, according to the European Society of Cardiology 2, 3

Fibrinolytic Strategy

• Fibrinolytic therapy should be initiated as soon as possible, preferably in the pre-hospital setting, as recommended by the European Society of Cardiology 2, 3
• A fibrin-specific agent (tenecteplase, alteplase, or reteplase) is recommended, according to the European Society of Cardiology 2, 3
• Oral or IV aspirin should be administered, as recommended by the European Society of Cardiology 2, 3
• Clopidogrel should be added to aspirin, according to the European Society of Cardiology 2, 3
• Anticoagulation should be administered until revascularization or for the duration of hospital stay (up to 8 days), as recommended by the European Society of Cardiology 2, 3

In-Hospital Management

• Routine echocardiography should be performed during hospitalization to assess LV and RV function, detect mechanical complications, and exclude LV thrombus, as recommended by the European Society of Cardiology 2, 3
• Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor should be maintained for 12 months, according to the European Society of Cardiology 2, 6
• High-intensity statin therapy should be initiated as early as possible, as recommended by the European Society of Cardiology 6
• Beta-blockers should be started orally in patients with heart failure and/or LVEF <40% unless contraindicated, according to the European Society of Cardiology 6
• ACE inhibitors should be started within 24 hours in patients with heart failure, LV systolic dysfunction, diabetes, or anterior infarct, as recommended by the European Society of Cardiology 6

Post-Discharge Management

• Antiplatelet therapy with low-dose aspirin (75-100 mg) should be continued indefinitely, as recommended by the European Society of Cardiology 6
• DAPT should be continued for 12 months after PCI unless there are contraindications, according to the European Society of Cardiology 6
• A proton pump inhibitor (PPI) should be used in combination with DAPT in patients at high risk of gastrointestinal bleeding, as recommended by the European Society of Cardiology 6
• LDL-C should be targeted to <1.8 mmol/L (70 mg/dL) or reduced by at least 50% if baseline is between 1.8-3.5 mmol/L, according to the European Society of Cardiology 6
• Smoking cessation counseling with pharmacological support should be provided, as recommended by the European Society of Cardiology 6
• Participation in a cardiac rehabilitation program is strongly recommended, according to the European Society of Cardiology 2, 6

Special Considerations

• In patients with cardiogenic shock, emergency angiography and PCI are recommended, as advised by the European Society of Cardiology 2, 3

Tenecteplase Action Time in ST-Elevation Myocardial Infarction

Administration and Dosage

• Tenecteplase is given as a single weight-adjusted intravenous bolus of 30-50mg (0.53 mg/kg bodyweight) 7
• For patients ≥75 years old, a 50% dose reduction is recommended to reduce the risk of stroke, as demonstrated in the STREAM trial 8

Adjunctive Therapy

• Tenecteplase should be administered with adjunctive antithrombotic therapy including aspirin and clopidogrel 7
• Anticoagulation with unfractionated heparin or enoxaparin should be continued for at least 48 hours and preferably for the duration of the index hospitalization (up to 8 days) 9

Monitoring and Reperfusion

• Monitoring for successful reperfusion should include assessment of symptom relief, hemodynamic stability, and reduction of at least 50% of the initial ST-segment elevation on follow-up ECG 60-90 minutes after administration 10

Acute ST-Elevation Myocardial Infarction (STEMI) Management

Initial Diagnosis and Assessment

• The European Society of Cardiology defines STEMI diagnosis by new or presumed new left bundle branch block, and isolated ST depression in anterior leads with ST elevation in aVR (suggesting left main or multivessel disease) 11, 12

Reperfusion Strategy Selection

• The European Society of Cardiology recommends primary PCI as the preferred reperfusion strategy when performed by an experienced team within 120 minutes of STEMI diagnosis, and fibrinolysis should be initiated immediately if the anticipated time from STEMI diagnosis to PCI exceeds 120 minutes 11

Primary PCI Strategy

• Routine radial access and drug-eluting stent implantation are the standard of care, and routine thrombus aspiration or deferred stenting are contraindicated 11

Special Considerations

• The European Society of Cardiology recommends emergency angiography and PCI in patients with cardiogenic shock, and a primary PCI strategy should be pursued in patients with cardiac arrest and ST-elevation on post-resuscitation ECG 11
• Women and men receive equal benefit from reperfusion and other STEMI-related therapies and should be managed equally 11

Common Pitfalls and Caveats

• Atypical presentations (especially in women, elderly, and diabetic patients) may lead to delayed diagnosis, and non-infarct related artery lesions should be evaluated before hospital discharge in stable patients 11

Management of ST-Elevation Myocardial Infarction (STEMI)

Special Considerations

• The American Heart Association recommends performing emergency angiography and PCI immediately regardless of time from symptom onset in patients with cardiogenic shock 13
• The American Heart Association suggests inserting intra-aortic balloon pump for hemodynamic stabilization in patients with cardiogenic shock 13
• The American Heart Association recommends considering alternative left ventricular assist devices for refractory cardiogenic shock 13
• The American Heart Association suggests administering fibrinolytic therapy if patient is unsuitable for either PCI or CABG in the absence of contraindications 13

In-Hospital Management

• The American College of Cardiology recommends obtaining fasting lipid profile within 24 hours of presentation 13
• The American Heart Association recommends providing anticoagulant therapy with vitamin K antagonist for patients with atrial fibrillation (CHADS2 score ≥2), mechanical heart valves, venous thromboembolism, or hypercoagulable disorder 13
• The American Heart Association suggests minimizing duration of triple-antithrombotic therapy (vitamin K antagonist + aspirin + P2Y12 inhibitor) to limit bleeding risk; considering 14 days for fibrinolysis patients, then transitioning to vitamin K antagonist plus single antiplatelet agent 13
• The American Heart Association recommends targeting INR 2.0-2.5 (lower than usual) when combining vitamin K antagonist with DAPT 13
• The American Heart Association suggests considering anticoagulation for patients with anteroapical akinesis or dyskinesis 13
• The American Heart Association recommends against using glucocorticoids and nonsteroidal anti-inflammatory drugs for treatment of pericarditis after STEMI 13

Arrhythmia Management

• The American College of Cardiology recommends implantable cardioverter-defibrillator therapy before discharge in patients who develop sustained ventricular tachycardia/ventricular fibrillation more than 48 hours after STEMI, provided the arrhythmia is not due to transient or reversible ischemia, reinfarction, or metabolic abnormalities 13

Pre-Discharge Risk Stratification

• The American Heart Association recommends performing noninvasive testing for ischemia before discharge in patients who have not had coronary angiography and do not have high-risk clinical features warranting angiography 13

STEMI Reperfusion and Early Management Guidelines

Diagnosis and Time‑Critical Actions

• Obtain a 12‑lead electrocardiogram within 10 minutes of first medical contact and define the moment of ST‑elevation (or equivalent) as “time zero” for all subsequent decisions. 14
• Recognize atypical ECG patterns that still indicate coronary occlusion—new left bundle‑branch block, hyper‑acute T‑waves, isolated anterior ST‑depression with ST‑elevation in aVR, or universal ST‑depression with aVR elevation—and pursue urgent primary PCI in these cases. 15

Initial Pharmacologic Measures

• Administer aspirin 150–325 mg orally (or 250–500 mg IV if the patient cannot swallow) immediately at first medical contact. 14
• Avoid routine supplemental oxygen unless peripheral oxygen saturation is < 90 %. 14

Reperfusion Strategy Selection (120‑Minute Rule)

• Primary PCI is the preferred reperfusion method when it can be performed ≤ 120 minutes from STEMI diagnosis. 15
• If the expected door‑to‑balloon time exceeds 120 minutes, initiate fibrinolysis within 10 minutes of diagnosis. 15

Systems of Care for Primary PCI

• Transfer patients directly to the catheterisation laboratory, bypassing the emergency department and intensive‑care unit; PCI‑capable centres must provide 24 / 7, no‑delay service. 14

Technical Standards During Primary PCI

• Use routine radial arterial access to minimise bleeding complications. 16
• Implant drug‑eluting stents (DES) as the default device. 16
• Routine thrombus aspiration and deferred stenting are contra‑indicated. 16

Antithrombotic Therapy for Primary PCI

• Give a potent P2Y12 inhibitor before or at the time of PCI: prasugrel 60 mg loading dose or ticagrelor 180 mg loading dose; clopidogrel only if the former agents are unavailable. 14
• Provide anticoagulation with unfractionated heparin 100 U/kg IV bolus (reduce to 60 U/kg if a GPIIb/IIIa inhibitor is used); enoxaparin or bivalirudin are acceptable alternatives, while fondaparinux is contraindicated for primary PCI. 14

Adjunctive Therapy When Fibrinolysis Is Used

• Combine fibrinolysis with aspirin (oral or IV) and clopidogrel (prasugrel/ticagrelor are not recommended with fibrinolysis). 14
• Use enoxaparin as the preferred anticoagulant (or unfractionated heparin if enoxaparin is unavailable). 14

Management of Non‑Infarct‑Related Artery (Non‑IRA) Lesions

• Evaluate severe non‑IRA stenoses (angiography or FFR) and consider revascularisation before hospital discharge, either during the index PCI or in a staged procedure. 16
• In the setting of cardiogenic shock, perform non‑IRA PCI during the index procedure. 16

Special Clinical Scenarios

Cardiac Arrest with STEMI

• Patients with a resuscitated cardiac arrest and ST‑elevation on the post‑resuscitation ECG should undergo immediate primary PCI. 14
• If ST‑elevation is absent but there is high suspicion of ongoing ischemia, perform urgent angiography within 2 hours. 15
• Initiate targeted temperature management early in unresponsive patients after cardiac arrest; avoid pre‑hospital cooling with large volumes of cold intravenous fluid. 14

Late Presentation (> 12 hours)

• Routine PCI of an occluded infarct‑related artery > 48 hours after symptom onset is not indicated in asymptomatic patients. 14
• PCI is warranted in patients with hemodynamic or electrical instability, or persistent symptoms, regardless of the time delay. 17

In‑Hospital Monitoring and Pharmacotherapy

Monitoring

• Monitor all STEMI patients for at least 24 hours after reperfusion therapy. 14

Dual Antiplatelet Therapy (DAPT)

• Continue aspirin 75–100 mg daily plus prasugrel 10 mg daily or ticagrelor 90 mg twice daily for 12 months after PCI. 14

Additional Evidence‑Based Medications

• Beta‑blockers should be started orally in patients with heart failure and/or left‑ventricular ejection fraction < 40 % unless contraindicated. 15
• ACE inhibitors should be initiated within 24 hours in patients with heart failure, left‑ventricular systolic dysfunction, diabetes, or anterior infarction. 15

Dose Adjustments in Special Populations

• Patients on oral anticoagulants, with renal insufficiency, or who are elderly require careful dose adjustments of antithrombotic therapies. 14

MINOCA (Myocardial Infarction with Non‑Obstructive Coronary Arteries)

• A substantial proportion of STEMI presentations have no significant coronary stenosis on urgent angiography; additional diagnostic testing is required to identify the underlying cause and tailor therapy. 14

Quality Improvement and Systems of Care

• Pre‑hospital STEMI care should be organised through regional networks that coordinate EMS and hospitals with standardised written protocols for rapid reperfusion. 14
• EMS must alert the PCI centre immediately after selecting the reperfusion strategy. 15
• Use validated quality indicators to measure and continuously improve STEMI care delivery. 14

Primary PCI versus Fibrinolytic Therapy in STEMI: Evidence‑Based Recommendations

Superior Clinical Outcomes

• Primary PCI achieves near‑normal coronary perfusion (TIMI 3 flow) in 70–90 % of STEMI patients, a rate substantially higher than with fibrinolytic therapy. 18
• In STEMI patients, especially those at high risk, primary PCI reduces all‑cause mortality compared with fibrinolysis. [19] [20] 21
• Primary PCI is associated with lower rates of recurrent myocardial infarction than fibrinolytic therapy. [19] [20]
• The need for emergency repeat revascularization (recurrent ischemia) is markedly lower after primary PCI versus fibrinolysis. [19] [20] 21

Safety Advantage

• The incidence of intracranial hemorrhage is dramatically lower with primary PCI than with fibrinolytic therapy. [19] [20] [18] [21]

Time‑Dependent Superiority

• Primary PCI is the preferred reperfusion strategy when the first‑medical‑contact‑to‑device time can be ≤120 minutes. 22
• For patients presenting directly to a PCI‑capable hospital, the target is ≤90 minutes from first medical contact to device deployment. 22
• If the anticipated PCI delay exceeds 120 minutes, fibrinolytic therapy becomes the preferred option provided it can be administered within 10–30 minutes of diagnosis. 22

Additional Clinical Benefits

• Immediate coronary angiography during primary PCI supplies diagnostic information on disease extent, spontaneous reperfusion, coronary vasospasm, or dissection. 18
• Successful primary PCI enables earlier hospital discharge and a faster return to normal daily activities. [19] [20]
• Primary PCI reduces complications related to prolonged ischemia or failed fibrinolysis. [19] [20]
• Fewer absolute contraindications limit the use of primary PCI compared with fibrinolytic agents. [19] [18]

Absolute Indications for Primary PCI (Regardless of Delay)

• Cardiogenic shock or acute severe heart failure at any time after symptom onset mandates primary PCI. [19] [20] 22
• Contraindications to fibrinolytic therapy in patients with ischemic symptoms ≤12 hours also require primary PCI irrespective of time. [19] [20] 22

System and Operator Requirements

• Outcomes are inferior in low‑volume hospitals or with inexperienced operators; high‑volume centers achieve the best results. [19] [20]
• 24/7 availability of a PCI‑capable facility is essential to preserve the mortality benefit of primary PCI. 22
• Direct transfer of the patient to the catheterization laboratory (bypassing the emergency department) is recommended to minimize delays. 22

Reperfusion and Management of STEMI with Active Gastrointestinal Bleeding

Reperfusion Strategy

• Primary percutaneous coronary intervention (PCI) is the preferred reperfusion method for patients with ST‑segment‑elevation myocardial infarction (STEMI) who have active gastrointestinal (GI) bleeding; fibrinolytic therapy is an absolute contraindication, and PCI should be performed regardless of the elapsed time from symptom onset. 23, 24
• Guidelines mandate primary PCI for STEMI patients with any contraindication to fibrinolysis, independent of the time from first medical contact. 23, 24
• Even when anticipated door‑to‑balloon delays exceed 120 minutes, PCI remains the sole viable reperfusion option in the setting of contraindicated fibrinolysis. 23, 25
• The mortality benefit of reperfusion (PCI) outweighs the procedural bleeding risk; untreated STEMI carries a substantially higher mortality than the bleeding complications associated with PCI. 25, 26

Immediate Diagnostic and Monitoring Actions (First 10 minutes)

• Give aspirin 150–325 mg orally or 250–500 mg intravenously immediately, despite active GI bleeding, because its mortality benefit in STEMI supersedes bleeding risk and it is essential for successful PCI. 26
• Obtain a 12‑lead electrocardiogram within 10 minutes and activate the catheterization laboratory without delay. 26
• Initiate continuous ECG monitoring equipped with defibrillation capability. 26
• Provide supplemental oxygen only if oxygen saturation falls below 90 %. 26

Antithrombotic Strategy Modifications

• Defer loading with a P2Y12 inhibitor until after diagnostic coronary angiography confirms the need for PCI, thereby minimizing unnecessary bleeding exposure. 26
• Use unfractionated heparin (70–100 U/kg IV bolus, a reduced dose compared with the standard 100 U/kg) because of its short half‑life and reversibility with protamine if bleeding worsens. 26
• Avoid bivalirudin and low‑molecular‑weight heparin (enoxaparin) in this context; unfractionated heparin’s reversibility makes it safer for patients with active bleeding. 26
• Do not use fondaparinux, which is contraindicated for primary PCI. 26

Post‑PCI Antiplatelet Management

• Administer a potent P2Y12 inhibitor (prasugrel or ticagrelor) immediately after successful PCI despite ongoing GI bleeding; the risk of early stent thrombosis outweighs the bleeding risk. 26
• Tailor the P2Y12 inhibitor dose to bleeding severity: consider reduced‑dose prasugrel (5 mg daily) or standard‑dose ticagrelor (90 mg twice daily). 26

Transfer and Procedural Timing

• Transfer the patient directly to the catheterization laboratory, bypassing the emergency department, to eliminate unnecessary delays. 25, 26
• PCI‑capable centers must perform the procedure without delay, 24 / 7, even during off‑hours (e.g., 2 am), because timely reperfusion is critical. 25, 26

Critical Pitfalls to Avoid

• Do not postpone PCI to “stabilize” the GI bleed; the mortality risk from STEMI exceeds that from the bleed, and guidelines require PCI irrespective of delay, especially in cardiogenic shock or acute severe heart failure. 23, 24, 25
• Do not withhold aspirin or P2Y12 inhibitors because of bleeding concerns; the immediate threat of stent thrombosis is greater than the manageable GI bleed. 26

Post‑Discharge Considerations

• Continue dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for 12 months unless a life‑threatening bleed recurs; premature discontinuation markedly raises the risk of stent thrombosis and mortality. 26

Reperfusion Strategy for STEMI Equivalents

Immediate Initial Management (First 10 minutes)

• Obtain and interpret a 12‑lead ECG within 10 minutes of first medical contact to identify STEMI‑equivalent patterns – ACC/AHA guideline recommendation. 27
• Give aspirin 150–325 mg orally (or 250–500 mg IV if the patient cannot swallow) immediately – ACC/AHA guideline recommendation. 28
• Activate the catheterization laboratory without delay – ACC/AHA guideline recommendation. 28

Timelines and Transfer Decisions

PCI‑Capable Facility

• Perform primary percutaneous coronary intervention (PCI) within 90 minutes of first medical contact for patients with STEMI equivalents – ACC/AHA Class I, Level A. 27
• Transfer the patient directly to the catheterization laboratory, bypassing the emergency department – ACC/AHA Class I, Level A. 28

Non‑PCI‑Capable Facility

• Transfer immediately for primary PCI if the anticipated first‑medical‑contact‑to‑device time is ≤120 minutes – ACC/AHA Class I, Level A. 27
• Maintain a door‑in‑door‑out time of ≤30 minutes to achieve the ≤120‑minute goal – ACC/AHA Class I, Level A. 28
• If primary PCI is expected to exceed 120 minutes, administer fibrinolytic therapy within 10–30 minutes of diagnosis – ACC/AHA Class I, Level A. 29

Situations Requiring Mandatory Primary PCI (Regardless of Delay)

• Cardiogenic shock or acute severe heart failure – ACC/AHA Class I, Level A. 27
• Contraindications to fibrinolytic therapy (e.g., active bleeding, recent stroke, terminal illness) – ACC/AHA Class I, Level A. 27
• Failed fibrinolysis (persistent symptoms or <50 % ST‑segment resolution at 60–90 minutes) – ACC/AHA Class I, Level A. 28

Antithrombotic Regimen for Primary PCI

• Give a potent P2Y12 inhibitor before or at the time of PCI – prasugrel 60 mg loading dose or ticagrelor 180 mg loading dose (clopidogrel only if the former are unavailable) – ACC/AHA Class I, Level A. 27
• Administer unfractionated heparin 100 U/kg IV bolus (reduce to 60 U/kg if a GPIIb/IIIa inhibitor is used) – ACC/AHA Class I, Level A. 27

Fibrinolytic Strategy When PCI Delay >120 Minutes

• Use a fibrin‑specific thrombolytic agent (tenecteplase, alteplase, or reteplase) within 10–30 minutes of diagnosis – ACC/AHA Class I, Level A. 30
• Plan transfer for coronary angiography 3–24 hours after successful fibrinolysis in stable patients – ACC/AHA Class I, Level A. 28
• Perform immediate rescue PCI if reperfusion fails (defined by <50 % ST‑segment resolution, hemodynamic instability, or refractory ischemia) – ACC/AHA Class I, Level A. 28

Hospital Mortality and Reperfusion Strategies in ST‑Elevation Myocardial Infarction (STEMI)

Impact of Hospital Volume

• In high‑volume centers (≥ 3 primary PCI procedures/month) the in‑hospital mortality for STEMI patients undergoing primary PCI is 3.4 %, compared with 6.2 % in low‑volume centers (< 1 PCI/month)【31】. (American Heart Association)

Outcomes in Cardiogenic Shock

• Among patients > 75 years presenting with cardiogenic shock, 56 % survive to hospital discharge and 75 % of those survivors are alive at 1 year after primary PCI【32】. (European Society of Cardiology)
• In cardiogenic shock, in‑hospital mortality varies by treatment strategy: 18.8 % with primary PCI, 32.5 % with medical therapy alone, and 19.2 % with surgical revascularization【32】. (European Society of Cardiology)
• Emergency primary PCI should be performed immediately, regardless of symptom‑onset time, in patients with cardiogenic shock【32】【33】. (European Society of Cardiology; American College of Cardiology)
• An intra‑aortic balloon pump (IABP) should be strongly considered for hemodynamic stabilization in cardiogenic shock【32】. (European Society of Cardiology)
• Alternative left‑ventricular assist devices are recommended for refractory cardiogenic shock when IABP is insufficient【32】. (European Society of Cardiology)
• In cardiogenic shock, a multi‑arterial PCI strategy (treating all significant lesions) is advised during the index procedure rather than limiting therapy to the culprit artery【32】. (European Society of Cardiology)

Effect of Treatment Delays

• In‑hospital mortality rises non‑linearly with door‑to‑balloon delay: 3.0 % at 30 min, 3.5 % at 60 min, 4.3 % at 90 min, 5.6 % at 120 min, 7.0 % at 150 min, and 8.4 % at 180 min【33】【34】. (American College of Cardiology; American Heart Association)
• The recommended door‑to‑balloon time for PCI‑capable hospitals is ≤ 90 minutes【33】【34】. (American College of Cardiology; American Heart Association)
• For patients requiring inter‑facility transfer, the first‑medical‑contact‑to‑device time should not exceed 120 minutes【33】【34】. (American College of Cardiology; American Heart Association)

Revascularization Recommendations for High‑Risk Patients

• Primary PCI is mandated (Class I) irrespective of delay for the following high‑risk presentations: cardiogenic shock, severe acute heart failure, contraindications to fibrinolysis, failed fibrinolysis, and cardiac arrest with ST‑segment elevation【33】. (American College of Cardiology)

All facts are drawn from peer‑reviewed sources and presented with the associated guideline societies where applicable.